It is therefore conceivable that these findings could, ultimately, be exploited not only to identify the response of various breast cancer cell types to TAM, but also to examine whether GLI1 expression may serve as marker of TAM sensitivity and/or resistance. This evidence concerns the gene GLI1 and breast cancer.